NLS Pharmaceutics Ltd

Research NLS Pharmaceutics Ltd (NCEL) on Bullrun: market cap USD 19.72M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerNCEL
• ExchangeNASDAQ
• CountrySwitzerland
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 19.72M
• Financial periodFY2025
• Net income-USD 8.30M
• Free cash flow-USD 2.77M

Valuation Snapshot

latest market cap is USD 19.72M.

About NLS Pharmaceutics Ltd

NewcelX Ltd., a biopharmaceutical company, engages in developing transformative stem-cell-derived therapies for Diabetes. The company develops NCEL-101, a cellular therapy product based on enriched pancreatic islet-like clusters for the treatment of Type 1 diabetes and Type 2 insulin dependent diabetes; AstroRx, an off-the-shelf cryopreserved cell therapy product for the treatment of Amyotrophic Lateral Sclerosis and neurodegenerative indications;

Frequently asked questions

What is NLS Pharmaceutics Ltd's market cap?

NLS Pharmaceutics Ltd's market capitalization is USD 19.72M.

What does NLS Pharmaceutics Ltd do?

NewcelX Ltd., a biopharmaceutical company, engages in developing transformative stem-cell-derived therapies for Diabetes.